CN115487226B - 一种外用天然杀菌剂药物组合物 - Google Patents
一种外用天然杀菌剂药物组合物 Download PDFInfo
- Publication number
- CN115487226B CN115487226B CN202211198936.0A CN202211198936A CN115487226B CN 115487226 B CN115487226 B CN 115487226B CN 202211198936 A CN202211198936 A CN 202211198936A CN 115487226 B CN115487226 B CN 115487226B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- extract
- semen cassiae
- extracting
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 44
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 35
- 239000003899 bactericide agent Substances 0.000 title claims abstract description 15
- 210000000582 semen Anatomy 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 241000465412 Hemsleya amabilis Species 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims description 55
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 15
- 241001111214 Fibraurea Species 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 241000222122 Candida albicans Species 0.000 claims description 11
- 229940095731 candida albicans Drugs 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 241000123862 Fibraurea recisa Species 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 2
- 239000000022 bacteriostatic agent Substances 0.000 claims description 2
- 230000003385 bacteriostatic effect Effects 0.000 claims description 2
- 230000002354 daily effect Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000005185 salting out Methods 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 230000002070 germicidal effect Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 23
- 229940079593 drug Drugs 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 6
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 238000003672 processing method Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 26
- 238000012360 testing method Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- 241000906682 Hemsleya Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 206010058679 Skin oedema Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 229940126589 solid medicine Drugs 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及药物组合物技术领域,具体涉及一种外用天然杀菌剂药物组合物。该外用天然杀菌剂药物组合物,其药物组成简单精炼,包括药物原料明子、黄藤以及雪胆,且上述药物均来源广泛易得,并且制备加工方法简单,各药物之间能够较好地发挥协同抗菌效果,所制备得到的药物组合物具有高效广谱的抑菌、杀菌效果,能够显著提高抗菌疗效指数,且耐药性明显降低,具有良好的临床开发应用潜力。
Description
技术领域
本发明涉及药物组合物技术领域,尤其涉及一种外用天然杀菌剂药物组合物。
背景技术
从弗莱明发现第一个抗生素来,人类在抗感染上取得了重大成果。但大量广谱抗生素、皮质类固醇激素、免疫抑制剂的广泛应用,导致抗生素耐药性迅速积累,真菌感染率也呈逐年上升,临床预期疗效丧失。提高抗生素新药开发速度和突破现有抗生素耐药性是解决临床抗感染的热点和难点。
长期的临床应用表明,来自于植物或动物的天然产物(例如黄连素)抗生素的耐药性积累没有人工合成物质那么强烈,同时,这些成分还能显著降低合成抗生素的耐药性,或者多组分使用常产生协同作用提高抗菌治疗能力,但目前可应用于临床的天然杀菌剂药物组合物较少,亟待进一步开发。
发明内容
为解决上述技术问题,本发明的目的在于提供一种外用天然杀菌剂药物组合物,所述外用天然杀菌剂药物组合物组成和制备方法简单,且具有高效广谱的抑菌、杀菌效果,具有良好的开发应用潜力。
为达到上述技术效果,本发明采用了以下技术方案:
第一方面,本发明提供一种外用天然杀菌剂药物组合物,所述药物组合物包括药物原料明子、黄藤以及雪胆中的至少两种。
进一步地,所述药物组合物包括药物原料明子、黄藤以及雪胆。
进一步地,所述药物组合物包括以下质量份数的药物原料:明子20~25份、黄藤10~12份以及雪胆1~2份。
进一步地,所述药物组合物还包括药学上可接受的辅料,并可被制备为任何药学上可以接受的外用剂型。
第二方面,本发明提供如一种上述药物组合物在制备杀菌制剂、抑菌制剂以及日化品方面的应用。
进一步地,所述杀菌制剂或抑菌制剂作用于革兰氏菌或真菌。
进一步地,所述革兰氏菌为铜绿假单胞菌、大肠杆菌、金黄色葡萄球菌中的任意一种,所述真菌为白色念珠菌。
第三方面,本发明还提供一种外用天然杀菌剂药物组合物的制备方法,具体包括:
将药物原料明子、雪胆混合后采用水提法进行提取以获得明子雪胆提取物;
取黄藤细粉采用酸解盐析法进行提取以获得黄藤提取物;
将明子雪胆提取物与黄藤提取物混合,即得所述药物组合物。
更具体地,所述外用天然杀菌剂药物组合物的制备方法包括以下步骤:
S1:雪胆提取物和黄藤提取物的制备:
其中,所述雪胆提取物的制备方法为:
按照质量份数取药物原料明子、雪胆粉碎后加水进行加热回流提取3~4小时,提取后冷却至室温,过滤,取滤液备用,得明子雪胆提取物;
所述黄藤提取物的制备方法为:
取黄藤细粉,按照黄藤细粉质量的2~5倍加入0.5%~0.7%硫酸溶液浸泡提取2~3次,每次提取8~10小时,提取温度为30℃~55℃,每次提取后均进行过滤,并将多次过滤获得的滤液进行合并,合并滤液后向其中加入10%体积的氯化钠,搅拌使滤液中的氯化钠达到饱和状态后静置4~5小时,过滤,留取沉淀,得到黄藤提取物;
S2:将明子雪胆提取物与黄藤提取物进行混合,以获得所述药物组合物。
与现有技术相比,本发明的有益效果为:
本发明提供的一种外用天然杀菌剂药物组合物,其药物组成简单精炼,包括药物原料明子、黄藤以及雪胆,且上述药物均来源广泛易得,并且制备加工方法简单,各药物之间能够较好地发挥协同抗菌效果,所制备得到的药物组合物具有高效广谱的抑菌、杀菌效果,能够显著提高抗菌疗效指数,且耐药性明显降低,具有良好的临床开发应用潜力。
具体实施方式
以下实施例仅用于更加清楚地说明本发明的技术方案,因此只作为示例,而不能以此来限制本发明的保护范围。所述实施例只用于解释本发明,并非用于限定本发明的范围。下述实施例中所使用的试验方法如无特殊说明,均为常规方法;所使用的材料、试剂或仪器未注明生产厂商者,如无特殊说明,为可从商业途径得到的试剂和材料,且实施例中未注明具体条件者,均按照常规条件或制造商建议的条件进行。
需要特别说明的是,本发明中所使用的药物原料明子为松明子;所使用的雪胆为雪胆属多种植物的干燥块茎;黄藤,为防己科植物黄藤的根茎。
实施例1
本实施例为本发明的制备实施例,本实施例具体提供以下多种提取物的制备:
提取物01为明子提取物,其制备方法为:
取药物原料明子粉碎,加水进行加热回流提取3~4小时,提取后冷却至室温,过滤,取滤液备用,得明子提取物。
提取物02为雪胆提取物,其制备方法为:
取药物原料雪胆粉碎,加水进行加热回流提取3~4小时,提取后冷却至室温,过滤,取滤液备用,得雪胆提取物。
提取物03为明子雪胆提取物,其制备方法为:
按照质量份数比例取明子、雪胆进行粉碎后,加水进行加热回流提取3~4小时,加水量为固体药物质量的2~5倍,提取后冷却至室温,过滤,取滤液备用,得明子雪胆提取物。
提取物04为黄藤提取物,其制备方法为:
取黄藤细粉,按照黄藤细粉质量的2~5倍加入0.5%~0.7%硫酸溶液浸泡提取2~3次,每次提取8~10小时,提取温度为30℃~55℃,每次提取后均进行过滤,并将多次过滤获得的滤液进行合并,合并滤液后向其中加入10%体积的氯化钠,搅拌使滤液中的氯化钠达到饱和状态后静置4~5小时,过滤,留取沉淀,干燥,得到黄藤提取物。
实施例2
本实施例为本发明的制备实施例,本实施例主要制备明子雪胆黄藤提取物,其制备方法如下:
药物组合物05为明子雪胆黄藤提取物,其制备方法为:
参照提取物03的制备方法制备明子雪胆黄藤提取物,并参照提取物04的制备方法制备黄藤提取物,然后将两者按照原药物的质量比例(明子20份、黄藤10份以及雪胆1份)进行对上述两种提取物进行混合,以获得明子雪胆黄藤提取物,即得药物组合物05。
药物组合物06为明子雪胆黄藤提取物,其制备方法为:
参照提取物03的制备方法制备明子雪胆黄藤提取物,并参照提取物04的制备方法制备黄藤提取物,然后将两者按照原药物的质量比例(明子25份、黄藤12份以及雪胆2份)进行对上述两种提取物进行混合,以获得明子雪胆黄藤提取物,即得药物组合物06。
实施例3
本实施例为本发明抑菌、杀菌试验实施例,具体操作以及测试结果如下:
3.1实验材料
(1)供试菌株:大肠杆菌、金黄色葡萄球菌、白色念珠菌、耐药白色念珠菌(14053)、铜绿假单胞菌。
(2)培养基:
(A)沙氏培养基(白色念珠菌、耐药白色念珠菌(14053)):蛋白胨10g/L、葡萄糖40g/L、琼脂15g/L;
(B)LB培养基(大肠杆菌、金黄色葡萄球菌、铜绿假单胞菌):蛋白胨10g/L、酵母提取物5g/L、氯化钠10g/L、琼脂15g/L。
(3)供试样品:提取物01、提取物02、提取物03、提取物04以及药物组合物05、药物组合物06;
(4)染料:0.1%吕氏碱性美兰染色液。
3.2试验方法
(1)菌株活化:大肠杆菌、金黄色葡萄球菌和铜绿假单胞菌接种于LB培养基,37℃恒温培养10-12h;白色念珠菌及其耐药菌接种至沙氏培养基),于28℃恒温培养10-12h;铜绿假单胞菌;备用。
(2)供试菌悬液的制备:取活化好的供试菌株适量分别于300μL 0.8%Nacl溶液中混悬,于80℃水浴锅中热杀1h,以制备死菌混悬液对照;同样取活化好的供试菌株适量分别于300μL 0.8%Nacl溶液中以制备活菌混悬液。
(3)活性测试
将01~06号提取物(或药物组合物)分别与5ul与大肠杆菌、金黄色葡萄球菌、白色念珠菌、耐药白色念珠菌活菌液混匀(药:菌液=1:1~10:1,V:V)滴加于载玻片上,取5ul菌液与5ul染色液,使其充分混合,盖上盖玻片放置3min。
3.3于高倍镜下观察,被染成蓝色的是死亡菌,无色的是活菌,15分钟内以视野中微生物染色多少为指标(细菌、真菌死亡百分数)考察药物的抑菌杀菌能力,结果见下表1:
表1提取物01~04、药物组合物05~06的抑菌、杀菌试验测试结果
该实验结果表明:本发明所提供的药物组合物中,明子雪胆之间可起到协同抗菌作用,待加入黄藤后,各药物之间的抑菌、杀菌效果更加明显,由此可知,本发明所提供的药物组合物中,其各组分具有明显的协同增效作用,能杀灭白色念珠菌等病原微生物,显著高于各药物组分单独使用的作用强度。
实施例4
本实施例为本发明提供的药物组合物的安全性试验实施例,具体操作以及测试结果如下:
4.1小鼠经口灌胃最大耐受量试验
ICR小鼠适应性饲养2天,选取禁食不禁水8小时后体重为18~21g小鼠20只,雌雄各半,按性别和体重随机分为溶媒对照组、样品给药组(选用药物组合物05进行测试),每组各10只。各组动物分别按40mL/kg容积灌胃给予纯水、药物组合物液,间隔6小时后再按同等剂量灌胃给药1次。样品给药组动物在给药后2小时均有不同程度腹泻粪便***,对照组正常***;两组均无明显毒性反应和死亡。在连续14天的观察期内,各组小鼠体重持续增长,两组在各时间点的体重增长无明显差异;对观察期结束处死动物的尸检亦未发现组织或脏器有明显异常。
4.2豚鼠皮肤过敏试验
4.2.1实验材料
选245~400g普通级豚鼠,按性别和体重分组:阴性对照组(纯水)、阳性对照组(2,4-二硝基氯苯,1%为致敏浓度,0.1%为激发浓度)以及样品给药组(选用药物组合物05进行测试),每组10只,雌雄各半。
4.2.2实验方法
每次致敏前24h给各组豚鼠背部脱毛,脱毛区大小为3×3cm2,并保持脱毛区皮肤完整。在试验第0、7、14天,将纯水、1%2,4-二硝基氯苯及实验药物分别涂抹于各组动物的脱毛区皮肤,给药量均为0.2mL/只,并用滤纸、保鲜膜、薄纱布覆盖固定,以保证药物与皮肤接触6小时后,温水冲洗去除剩余药物。试验第28天(末次给药后14天),再次同法分别涂抹各种药物于豚鼠脱毛区皮肤进行激发,观察给药后6、24、48、72小时的皮肤过敏反应情况及发生率。
试验期间阴性对照、阳性对照和样品给药组动物进食、行为活动及精神状态良好;各组动物体重均有增长,除阳性对照组后期体重增长有缓慢趋势外,其余各给药组与阴性对照组相比无显著差异。
阳性对照组所有动物在相应观察点均有不同程度的皮肤水肿或红斑出现,致敏率为100%。阴性对照及样品给药组在激发后6、24、48、72h的观察点均未见皮肤红斑和水肿发生,致敏率为0,说明药物组合物样品与豚鼠皮肤接触无致敏性。
4.3家兔皮肤刺激性试验
4.3.1实验方法
采用同体自身对比法,将2.80-3.45kg日本大耳白兔8只分为完整皮肤及破损皮肤组,每组4只,雌雄各半。试验前对家兔背部去毛,范围各20×15cm2。将完整皮肤组和破损皮肤组的背部皮肤均分为5块:上、左中、右中、左下、右下。破损皮肤组用灭菌手术刀片在5块皮肤上各划一个“井”字形创口,范围2cm×2cm,以轻度渗血为度。
各组均取0.5mL纯水涂于去毛区上部;实验组使用药组组合物05进行测试,每次取0.5mL涂于去毛区左中部,涂药后以纱布覆盖,用无刺激性胶布加以固定,分笼饲养,保持药物贴敷时间4h后,用温水清洁给药部位。连续7天重复以上操作,视情况对给药部位进行重复脱毛。每次给药前及去除药物后1h,以及末次贴敷去除药物后1h、24h、48h、72h,观察并记录涂敷部位皮肤有无红斑和水肿等情况、计算每一观察时间点各组积分均值及观察期内每天每只动物刺激积分均值;观察结束后颈动脉放血处死动物,取给药部位皮肤外委进行组织病理学检查。
4.3.2实验结果
样品给药组和纯水对照连续7天涂皮给药,完整皮肤和破损皮肤给药组家兔体重均有增加,两组家兔处死前的体重及给药前体重比较,均无统计学差异。
样品给药组连续7天涂皮给药,完整皮肤组各给药部位均未见明显红斑和水肿;各样品对破损皮肤组给药部位均有少数动物出现轻微的红斑或水肿;按“皮肤刺激强度评价标准”,所有实验药物与皮肤接触给药对破损皮肤和完整皮肤均无刺激性。
给予实验药物和纯水的家兔破损皮肤和完整皮肤均可见表皮轻度增厚,真皮***层中多量以淋巴细胞、中性粒细胞为主的间质浸润。各给药部位与纯水部位相比,组织学改变的发生率及程度基本相当。
对日本大耳白兔破损和完整皮肤按0.5mL/只.日、连续7天涂皮给予实验药物,在给药皮肤局部未观察到与药物有关的组织学改变,说明实验药物与家兔皮肤接触给药无刺激性。
综上所述,经过上述动物实验验证,本发明提供的药物组合物对皮肤过敏性、刺激性非常小,安全性高。
以上实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的宗旨和范围,其均应涵盖在本发明的权利要求范围当中。本发明未详细描述的技术、形状、构造部分均为公知技术。
Claims (5)
1.一种外用天然杀菌剂药物组合物,其特征在于:所述药物组合物由以下质量份数的药物原料制成:明子20~25份、黄藤10~12份以及雪胆1~2份。
2.如权利要求1所述的一种外用天然杀菌剂药物组合物,其特征在于:所述药物组合物还包括药学上可接受的辅料,并可被制备为任何药学上可以接受的外用剂型。
3.如权利要求1~2任意一项所述的药物组合物在制备杀菌制剂、抑菌制剂以及日化品方面的应用;
所述杀菌制剂或抑菌制剂作用于革兰氏菌或真菌;
所述革兰氏菌为铜绿假单胞菌、大肠杆菌、金黄色葡萄球菌中的任意一种,所述真菌为白色念珠菌。
4.如权利要求1~2任意一项所述的一种外用天然杀菌剂药物组合物的制备方法,其特征在于,包括:
将药物原料明子、雪胆混合后采用水提法进行提取以获得明子雪胆提取物;
取黄藤细粉采用酸解盐析法进行提取以获得黄藤提取物;
将明子雪胆提取物与黄藤提取物混合,即得所述药物组合物。
5.如权利要求4所述的一种外用天然杀菌剂药物组合物的制备方法,其特征在于,包括以下步骤:
S1:明子雪胆提取物的制备:
按照质量份数取药物原料明子、雪胆粉碎后加水进行加热回流提取3~4小时,提取后冷却至室温,过滤,取滤液备用,得明子雪胆提取物;
黄藤提取物的制备:
取黄藤细粉,按照黄藤细粉质量的2~5倍加入0.5%~0.7%硫酸溶液浸泡提取2~3次,每次提取8~10小时,提取温度为30℃~55℃,每次提取后均进行过滤,并将多次过滤获得的滤液进行合并,合并滤液后向其中加入10%体积的氯化钠,搅拌使滤液中的氯化钠达到饱和状态后静置4~5小时,过滤,留取沉淀,得到黄藤提取物;
S2:将明子雪胆提取物与黄藤提取物进行混合,以获得所述药物组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211198936.0A CN115487226B (zh) | 2022-09-29 | 2022-09-29 | 一种外用天然杀菌剂药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211198936.0A CN115487226B (zh) | 2022-09-29 | 2022-09-29 | 一种外用天然杀菌剂药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115487226A CN115487226A (zh) | 2022-12-20 |
CN115487226B true CN115487226B (zh) | 2024-01-12 |
Family
ID=84472547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211198936.0A Active CN115487226B (zh) | 2022-09-29 | 2022-09-29 | 一种外用天然杀菌剂药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115487226B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1108953A (zh) * | 1994-12-15 | 1995-09-27 | 廖忠志 | 一种跌打药及其制备方法 |
CN1164416A (zh) * | 1997-04-01 | 1997-11-12 | 攀枝花市地方病防治所 | 一种防治痤疮皮肤病的化妆品及其生产方法 |
CN101007130A (zh) * | 2005-12-16 | 2007-08-01 | 湖南九典制药有限公司 | 一种抗菌消炎的中药组合物及其制备方法 |
CN107468724A (zh) * | 2017-07-31 | 2017-12-15 | 陈猛 | 一种烧伤精粉及制备方法 |
-
2022
- 2022-09-29 CN CN202211198936.0A patent/CN115487226B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1108953A (zh) * | 1994-12-15 | 1995-09-27 | 廖忠志 | 一种跌打药及其制备方法 |
CN1164416A (zh) * | 1997-04-01 | 1997-11-12 | 攀枝花市地方病防治所 | 一种防治痤疮皮肤病的化妆品及其生产方法 |
CN101007130A (zh) * | 2005-12-16 | 2007-08-01 | 湖南九典制药有限公司 | 一种抗菌消炎的中药组合物及其制备方法 |
CN107468724A (zh) * | 2017-07-31 | 2017-12-15 | 陈猛 | 一种烧伤精粉及制备方法 |
Non-Patent Citations (1)
Title |
---|
刘双柱.《刘双柱医集》.陕西科学技术出版社,2021,(第1版),143页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115487226A (zh) | 2022-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110585114B (zh) | 一种调节皮肤微生物菌群的杀菌组合物及其应用 | |
KR101864409B1 (ko) | 한방 추출물 및 미생물 발효추출물을 유효성분으로 함유하는 항균, 살균 또는 항진균용 조성물 | |
CN109568206A (zh) | 一种专用于女性的抑菌组合物及洗液和制备方法 | |
CN107961399A (zh) | 一种含复合抗菌剂的水性人体润滑液 | |
CN113081928A (zh) | 一种植物抑菌凝胶及其制备方法和应用 | |
CN111449973A (zh) | 一种修复女性***微生态平衡的泡沫剂及其制备方法 | |
JPH06279256A (ja) | 皮膚外用剤 | |
CN112915055A (zh) | 一种舒缓多效除螨组合物及其应用 | |
CN107375059B (zh) | 一种艾叶防脱洗发液及其制备方法 | |
KR102148808B1 (ko) | 천연 항균제를 포함하는 여성청결제 조성물 | |
CN109077945A (zh) | 用于化妆品的溶菌酶组合抑菌剂 | |
CN101543658A (zh) | 防治***的宫颈帽及其制备方法 | |
CN108542805B (zh) | 祛痘复方精油制剂及其制备方法和应用 | |
CN113616568A (zh) | 一种抗炎祛痘组合物及其制备方法 | |
CN106176603A (zh) | 一种植物精油微乳凝胶及其制备方法和应用 | |
CN111317675B (zh) | 一种含d-泛醇的祛痘组合物及其应用与含有该组合物的化妆品 | |
WO2003082304A1 (en) | Antimicrobial compositions and methods of use | |
CN115487226B (zh) | 一种外用天然杀菌剂药物组合物 | |
CN106267329A (zh) | 一种植物精油凝胶敷料及其制备方法和应用 | |
JP2019178170A (ja) | 抗微生物作用を備えた組成物の製造のためのパチョリ抽出物の使用 | |
CN110339121A (zh) | 抗菌组合物及其制备方法与应用 | |
CN113456735B (zh) | 一种灭活益生菌草本凝胶及其制备方法和应用 | |
CN115414308A (zh) | 一种祛痘组合物及制备方法和应用 | |
CN108939145A (zh) | 一种液体创可贴及其制备方法 | |
CN113230200A (zh) | 一种治疗细菌性皮肤病的软膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |